
NanoString Blog
Category: Oncology

Oncology
miRNA Profiling in Malignant Melanoma: Making “Australia’s National Cancer” Obsolete.
Australia is a sun-worshipping country, the world capital for beautiful beaches, athletic surfers, cute marsupials, and the occasional weird-looking animal. But it is also the capital for something less pleasant:…

Oncology
Mapping the miRNA-mRNA Interactome in Multiple System Atrophy
A rapidly developing and fatal neurodegenerative disorder, MSA is frequently misdiagnosed or undetected until later stages due to its systemic nature, undefined etiopathogenesis, and multifaceted clinical presentation. In an attempt…

Oncology
Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Dr. Lisa Butterfield, PhD recently joined the Parker Institute for Cancer Immunotherapy as Vice President focusing on cell therapies while she continues her independent cancer vaccine research as an Adjunct…

Oncology
Q&A with Drs. Torsten Nielsen and Tony Ng and Angela Goytain: Development of a Sarcoma Gene Fusion Assay Faster Than FISH and Simpler than NGS
The NanoString nCounter is Research Use Only and not for diagnostic use. The views expressed herein are solely those of the interviewed researchers. Torsten Nielsen, MD, PhD is a pathologist…

Oncology
Q&A with Dr. Juliane Nguyen: Exosome Profiling with miRNA and Biotech’s Next Breakthrough
Dr. Juliane Nguyen is a professor in the Department of Pharmaceutical Sciences at the University of Buffalo. Her Therapeutic Biomaterials Laboratory investigates using exosomes and other nanoscale carriers for the…

Oncology
The IO Revolution, Part 3 of 4: The Role of the Tumor in the Cancer Immunity Cycle
Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. Part two further examined the role of the host, and in this…

Oncology
The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle
Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these…

Miscellaneous Oncology
Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy
President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer…

Oncology
The Cancer Immunogram: A Picture of Personalized Medicine
What do we already know about tumor-immune system interactions, and how can this information be used to help guide us toward the best therapeutic choice? That is exactly the question…

Oncology
The IO Revolution, Part 1 of 4: Opportunities and Challenges
Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.